Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Drug developers have discovered the immunological mechanism that underlies the ability of the candidate drug PV-10 to induce regression of primary and secondary melanoma tumors.

PV-10, which was developed by Provectus Pharmaceuticals, Inc., (Knoxville, TN, USA) is a 10% solution of Rose Bengal formulated for IL (intralesional) injection. Rose Bengal is a water-soluble xanthene dye that had been previously employed in liver function studies and is still in use by ophthalmologists.

Investigators at the Moffitt Cancer Center (Tampa, FL, USA) worked with two different mouse models: BALB/c mice bearing MT-901 breast cancer and C57BL/6 mice that had been injected with B16 melanoma cells to establish one subcutaneous primary tumor and multiple secondary lung lesions.

Results published in the July 17, 2013, online edition of the journal PLOS ONE revealed that treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases.

Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma (interferon-gamma) production compared to splenocytes from saline-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T-cells isolated after PV-10 treatment was observed. Transfer of T-cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in untreated mice bearing B16 melanoma.

The investigators concluded that these studies established that IL PV-10 therapy induced tumor-specific T-cell-mediated immunity, which supported the concept of combining IL PV-10 with immunotherapy for advanced malignancies. “Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said senior author Dr. Shari Pilon-Thomas, assistant member of the immunology program at the Moffitt Cancer Center.

Related Links:
Provectus Pharmaceuticals, Inc.
Moffitt Cancer Center


RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.